CTC-501
Phase 3- Indications
- Major Depressive Disorder
Company intelligence / Profile preview
Chase Therapeutics
Washington, DC, United Stateschasetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Chase Therapeutics is advancing two lead drug candidates—CTC-501 for Major Depressive Disorder and CTC-413 for Parkinson’s Disease—both entering or preparing for Phase 3 pivotal trials. CTC-501 has shown rapid symptomatic relief in MDD with good tolerability, while CTC-413 demonstrated effective symptom mitigation and neuroprotective potential in proof-of-concept trials. The company is also developing a novel diagnostic tool to improve early detection of Parkinson's Disease.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesDiagnostic products (for Parkinson’s Disease)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Chinalink Asia Holdings led Series B financing round; no major pharma partnerships disclosed but investors include Brain Trust Accelerator Fund II, Rise of the Rest Fund, Makana Holdings.
Beyond the preview
Go deeper on Chase Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chase Therapeutics.